Dragonboat Biopharmaceutical

Dragonboat Biopharmaceutical is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of therapeutic antibodies and biologics. As a core subsidiary of Mabwell (Shanghai) Bioscience, the company focuses on high-value biosimilars and innovative biologics targeting oncology, autoimmune diseases, and ophthalmology. Their portfolio includes several advanced programs, including biosimilars for adalimumab and denosumab, as well as novel bispecific antibodies. Dragonboat leverages integrated capabilities in drug discovery, process development, and GMP manufacturing to advance its pipeline from research to commercialization. The company plays a pivotal role in Mabwell's broader strategy to provide affordable and effective biological therapies to global markets.